

From: [Kristin Rademacher](#)
To: [AGO - High Cost Prescription Drugs](#)
Cc: [SPTR.ANI](#); sharon.feldman@anipharma.com; [Annie Praino](#); [Melody Peters](#)
Subject: Notice of New Drug Introduction Pursuant to 18 V.S.A § 4637(b)
Date: Wednesday, May 8, 2024 5:08:48 PM
Attachments: [image001.jpg](#)
[image002.png](#)
[image003.png](#)
[image004.png](#)
[image005.png](#)

Some people who received this message don't often get email from kristin.rademacher@rldatixlifesciences.com.
[Learn why this is important](#)

EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.

To the Office of the Attorney General:

Pursuant to 18 V.S.A § 4637(b), ANI Pharmaceuticals, Inc. provides notice that it intends to introduce to market the following on 05/02/2024 at a wholesale acquisition cost that exceeds the Medicare Part D Specialty Drug threshold:

| NDC | Product Name | Product Description |
|----------------------|--------------------------|-----------------------------------|
| 62559020403 300mL | Baclofen Oral Suspension | Baclofen Oral Suspension 25mg/5mL |

Please reach out if you have any questions.

Regards,

Kristin Rademacher | *Senior Analyst, Price Transparency*

T: +1-856-206-5660 | E: kristin.rademacher@rldatixlifesciences.com | L: [Kristin Rademacher](#)

